Enanta Pharmaceuticals Reports Q3 Fiscal 2025 Results with $18.3M Revenue

Enanta Pharmaceuticals, Inc. reported its financial results for the third quarter of fiscal 2025, revealing a total revenue of $18.3 million, a slight increase from $18.0 million in the same period last year. The company's royalty revenue, primarily derived from its collaboration with AbbVie for the hepatitis C treatment MAVYRET/MAVIRET, was $18.3 million for the quarter, compared to $17.9 million in the prior year. For the nine months ended June 30, 2025, total revenue decreased to $50.2 million from $53.0 million in the previous year, attributed to lower reported sales of HCV treatments by AbbVie.

Operating expenses for the quarter were $37.2 million, down from $42.2 million in the same quarter of 2024. Research and development expenses decreased to $27.2 million from $28.7 million, reflecting a reduction in costs associated with clinical trials, particularly in the company's respiratory syncytial virus (RSV) programs. General and administrative expenses also saw a decline, falling to $10.0 million from $13.4 million, primarily due to reduced legal expenses related to ongoing litigation. The net loss for the quarter was $18.3 million, an improvement from a net loss of $22.7 million in the same period last year.

Enanta's balance sheet as of June 30, 2025, showed total assets of $301.0 million, down from $376.7 million at the end of the previous fiscal year. The company had cash, cash equivalents, and short-term marketable securities totaling $204.1 million, which it expects will be sufficient to fund operations into fiscal 2028. The decrease in total assets was largely due to a reduction in short-term marketable securities, which fell to $159.3 million from $210.9 million. The company's accumulated deficit increased to $386.2 million from $323.0 million, reflecting ongoing operational losses.

Strategically, Enanta entered into a royalty sale agreement with an affiliate of OMERS in April 2023, receiving $200 million in exchange for 54.5% of future royalty payments from MAVYRET/MAVIRET sales through June 2032. This agreement has been recorded as a liability on the balance sheet, which will be amortized over the term of the agreement. The company continues to focus on advancing its clinical programs, including two candidates for RSV, zelicapavir and EDP-323, both of which have received Fast Track designation from the FDA.

Looking ahead, Enanta anticipates continued operational losses as it invests in its research and development programs. The company is actively evaluating potential partnerships to advance its RSV programs and expects to maintain a focus on its immunology initiatives. Enanta's management remains optimistic about its financial position, supported by its existing cash reserves and anticipated royalty revenues, while acknowledging the inherent risks and uncertainties in the biotechnology sector.